Zavegepant
Zavzpret (zavegepant) is a small molecule pharmaceutical. Zavegepant was first approved as Zavzpret on 2023-03-09. It is used to treat migraine with aura and migraine without aura in the USA. It is known to target calcitonin gene-related peptide type 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Zavzpret
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| migraine with aura | EFO_0005295 | D020325 | G43.1 |
| migraine without aura | EFO_0005296 | D020326 | G43.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ZAVEGEPANT HYDROCHLORIDE, ZAVZPRET, PFIZER | |||
| 2028-03-09 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 2 | 3 | — | — | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zavegepant |
| INN | zavegepant |
| Description | Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. Zavegepant is a calcitonin gene-related peptide receptor antagonist. It is sprayed into the nose. It is sold by Pfizer.
|
| Classification | Small molecule |
| Drug class | calcitonin gene-related peptide receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12 |
Identifiers
| PDB | — |
| CAS-ID | 1337918-83-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2397415 |
| ChEBI ID | — |
| PubChem CID | 53472683 |
| DrugBank | DB15688 |
| UNII ID | ODU3ZAZ94J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CALCRL
CALCRL
Organism
Homo sapiens
Gene name
CALCRL
Gene synonyms
CGRPR
NCBI Gene ID
Protein name
calcitonin gene-related peptide type 1 receptor
Protein synonyms
calcitonin receptor-like, Calcitonin receptor-like receptor, CGRP type 1 receptor
Uniprot ID
Mouse ortholog
Calcrl (54598)
calcitonin gene-related peptide type 1 receptor (Q9WUP2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 102 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use